All News

Pharmacists enhance community health by offering test-and-treat services for COVID-19, influenza, strep, and RSV, improving access to care.

Discover how hydroxyapatite toothpaste tablets revolutionize oral care with eco-friendly, effective, and gentle alternatives to traditional fluoride toothpaste.

Pharmacists enhance health care delivery by managing medication refills, addressing drug shortages, and supporting chronic disease management.

New research reveals circulating tumor cells can predict patient response to tarlatamab in small cell lung cancer, enhancing personalized treatment strategies.

In this episode, we break down the genetics, diagnosis, and clinical impact of HCM, explore how management strategies have evolved, and discuss the emerging role of cardiac myosin inhibitors in treating obstructive disease.

Discover how ENAMEL revolutionizes oral care with eco-friendly, waterless toothpaste tablets made from clean, natural ingredients.

Improving Health Equity Through Pharmacist-Led Care Is a Collective Necessity Requiring a Multifaceted, Collaborative Approach

Recent research reveals no significant link between prenatal acetaminophen use and increased risks of autism or ADHD in children, challenging FDA claims.

New research reveals PUF60's critical role in triple-negative breast cancer, highlighting RNA splicing as a promising therapeutic target for oncology.

Ali Dehghani, DO, highlights that shingles vaccination not only prevents rash but is also associated with lower risks of major cardiovascular events, dementia, and mortality, underscoring pharmacists’ role in patient counseling and preventive care.

The FDA approved oral semaglutide to reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D).

Innovative digital twin technology revolutionizes brain cancer treatment by predicting tumor metabolism and personalizing therapies for better patient outcomes.

High out-of-pocket costs lead patients to skip medications. Financial assistance programs improve adherence, but complex insurance strategies may hinder access.

The glucagon-like peptide-1 (GLP-1) receptor agonist medications evaluated included semaglutide, tirzepatide, and liraglutide.

Nina Masters, PhD, MPH, explains how early adherence to pediatric vaccines strongly predicts timely measles-mumps-rubella (MMR) vaccination.

Preeclampsia significantly raises the risk of chronic kidney disease (CKD) later in life, highlighting the need for targeted postpartum monitoring for affected women.

The epcoritamab, rituximab, and lenalidomide regimen provides a chemo-free, outpatient option for relapsed or refractory follicular lymphoma (FL), offering high response rates, improved quality of life, and expanding pharmacists’ roles in patient management.

Food insecurity and social instability significantly increase long COVID risk in children, highlighting the need for targeted public health interventions.

Hawaii has secured a $700 million settlement with the manufacturers of Plavix following a lawsuit alleging they concealed for years the drug's ineffectiveness and potential danger for individuals of East Asian or Pacific Islander descent, a risk that the FDA later required to be disclosed with a boxed warning.

A tour through GLP-1’s unexpected biology.

Polypharmacy poses significant risks for patients, highlighting the need for comprehensive medication reviews and patient involvement.

Teclistamab-cqyv shows promising results in treating refractory multiple myeloma, significantly improving survival rates and offering new hope for patients.

Ben Long, MD; and Weston Blakeslee, PhD, discuss how personalized text reminders significantly improve prescription adherence in patients with heart failure and the critical role pharmacists play in reinforcing engagement.

According to the news release, the manufacturers have 30 days to respond.

Jeffery A. Goad, PharmD, MPH, stresses that consistent, evidence-based communication from pharmacists and other health care professionals is essential to maintaining public trust and preventing declines in childhood vaccination.

In October 2025, the FDA approved an updated label update for capecitabine mandating DPYD genetic testing before initiating treatment, unless urgent.

Explore the differences between oral and injectable semaglutide for weight management, focusing on adherence, adverse effects, and patient preferences.